OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1
CA244-0001
Phase 2 small_molecule active
Quick answer
OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1 for Advance solid tumors is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Advance solid tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active